FGFR2
- [1]. Katoh Y, et al. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med. 2009 Mar;23(3):307-11. [Content Brief]
- [2]. Xie Y, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020 Sep 2;5(1):181. [Content Brief]
- [3]. Egan JB, et al. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017;2017. [Content Brief]
- [4]. Liao RG, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15;73(16):5195-205. [Content Brief]
-
FGFR2 Verwandte Produkte (33)
Verwandte Produkte (33)
- 1
- 2
-
Nintedanib
0 ImagesSynonyms: BIBF 1120; IntedanibNintedanib (BIBF 1120; Intedanib) is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Ferulic acid
0 ImagesFerulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib esylate
0 ImagesSynonyms: BIBF 1120 esylate; Intedanib esylateNintedanib esylate (BIBF 1120 esylate; Intedanib esylate) is an orally active receptor tyrosine kinase inhibitor. Nintedanib esylate inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib esylate exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib esylate ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib esylate can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib-d8
0 ImagesSynonyms: BIBF 1120-d8; Intedanib-d8Nintedanib-d8 (BIBF 1120-d8; Intedanib-d8) is the deuterated-labeled Nintedanib (HY-50904). Nintedanib is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
BR-cpd7
0 ImagesArt. -Nr.: HY-163705Reinheit: 98.01%BR-cpd7 is an orally active, selective PROTAC degrader targeting FGFR1 and FGFR2, with a DC50 of 2.2 nM against FGFR1. BR-cpd7 reduces FGFR signaling. BR-cpd7 induces cell cycle arrest and selectively blocks the proliferation of FGFR1/FGFR2-dependent tumor cells. BR-cpd7 exhibits significant antitumor efficacy in FGFR1-dependent lung cancer animal models, while achieving complete depletion of FGFR1. BR-cpd7 can be used for cancer-related research. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
- S49076
-
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
DGY-09-192
0 ImagesDGY-09-192 is a PROTAC FGFR1/2 degrader (FGFR1: DC50 = 4.35 nM; FGFR2: DC50 = 70 nM). DGY-09-192 preferentially degrades wild-type FGFR1/2 and multiple FGFR2 fusion proteins (including FGFR2-PHGDH and FGFR2-OPTN). DGY-09-192 suppresses downstream FGFR signaling (reducing phosphorylation of FRS2 Y196 and ERK1/2 T202/Y204) in vitro and vivo. DGY-09-192 can be used for the study of FGFR-driven cancers. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib-13C,d3
0 ImagesArt. -Nr.: HY-50904S1Synonyms: BIBF 1120-13C,d3; Intedanib-13C,d3Nintedanib-13C,d3 (BIBF 1120-13C,d3; Intedanib-13C,d3) is the 13C, deuterated-labeled Nintedanib (HY-50904). Nintedanib is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib-d3
0 ImagesSynonyms: BIBF 1120-d3; Intedanib-d3Nintedanib-d3 (BIBF 1120-d3; Intedanib-d3) is the deuterated-labeled Nintedanib (HY-50904). Nintedanib is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib (Standard)
0 ImagesSynonyms: BIBF 1120 (Standard); Intedanib (Standard)Nintedanib (Standard) (BIBF 1120 (Standard); Intedanib (Standard)) is the analytical standard of Nintedanib (HY-50904). This product is intended for research and analytical applications. Nintedanib (BIBF 1120; Intedanib) is an orally active receptor tyrosine kinase inhibitor. Nintedanib inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
HuGAL-FR21
0 ImagesArt. -Nr.: HY-P991584HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Lavengratinib
0 ImagesArt. -Nr.: HY-187793CAS. Nr.: 2412854-49-8Synonyms: ABSK061Lavengratinib (ABSK061) is a FGFR2/FGFR3 inhibitor. Lavengratinib selectively inhibits FGFR2 and FGFR3 signaling pathways and reduces the risk of FGFR1-mediated hyperphosphatemia. Lavengratinib is suitable for research on advanced solid tumors (including cholangiocarcinoma, gastric cancer, non-small cell lung cancer, cervical cancer and urothelial cancer). -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Nintedanib-d3 esylate
0 ImagesArt. -Nr.: HY-11106SSynonyms: BIBF 1120-d3 esylate; Intedanib-d3 esylateNintedanib-d3 esylate (BIBF 1120-d3 esylate; Intedanib-d3 esylate) is the deuterated-labeled Nintedanib esylate (HY-11106). Nintedanib esylate is an orally active receptor tyrosine kinase inhibitor. Nintedanib esylate inhibits FGFR1-3, PDGFRα/β, and VEGFR1-3 through competitive binding to the ATP pocket, and blocks PI3K/Akt/mTOR phosphorylation. Nintedanib esylate exhibits anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects, reducing collagen deposition, fibroblast activation, angiogenesis, airway inflammation and hyperresponsiveness, and cytokine/chemokine expression. Nintedanib esylate ameliorates Bleomycin (HY-108345)-induced lung injury and dystrophic muscle pathology; it also delays tumor growth and prolongs survival, and immune checkpoint blockade enhances its antitumor efficacy. Nintedanib esylate can be used in research on pulmonary fibrosis, cancer, systemic sclerosis, chronic asthma, and rheumatoid arthritis-associated interstitial lung disease. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Multi-kinase-IN-15
0 ImagesArt. -Nr.: HY-131571CAS. Nr.: 1613168-52-7Multi-kinase-IN-15 is an orally active multi-kinase inhibitor. Multi-kinase-IN-15 inhibits the kinase activity of MNK1, MNK2, ABL1, ABL1 T315I, FLT3, VEGFR2, RET, cKIT, FGFR2, PDGFRα, and PDGFRβ. Multi-kinase-IN-15 dose-dependently reduces phosphorylation of eIF4E and phosphorylated Crkl in tumor cells, and decreases phosphorylation of eIF4E in tumor tissues. Multi-kinase-IN-15 inhibits tumor growth. Multi-kinase-IN-15 can be used for research on chronic myeloid leukemia. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
Dabogratinib (GMP)
0 ImagesArt. -Nr.: HY-159642GCAS. Nr.: 2800223-30-5Synonyms: TYRA-300 (GMP)Dabogratinib (GMP) is the GMP-grade version of Dabogratinib (HY-159642). Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
FGFR-IN-27
0 ImagesArt. -Nr.: HY-183780FGFR-IN-27 is an orally active, broad-spectrum FGFR inhibitor, with an IC50 of 0.24 nM against human FGFR1, 0.71 nM against FGFR2, 0.87 nM against FGFR3, and 6.50 nM against FGFR4. FGFR-IN-27 inhibits cancer cell proliferation and blocks tumor growth. FGFR-IN-27 reduces the phosphorylation levels of AKT and ERK, induces apoptosis and ferroptosis, increases ROS levels, and decreases GSH levels. FGFR-IN-27 can be used in the research of hepatocellular carcinoma. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
FGFR-IN-28
0 ImagesArt. -Nr.: HY-184250CAS. Nr.: 2634677-16-8FGFR-IN-28 is a FGFR inhibitor with inhibitory activity against multiple subtypes of the FGFR family, with an IC50 of 4.4 nM against FGFR4. FGFR-IN-28 inhibits kinase activity and phosphorylation processes, and blocks the downstream MAPK and AKT signaling pathways. FGFR-IN-28 induces cellular DNA damage, cell cycle arrest, apoptosis and ferroptosis, and reduces the adhesion, invasion and metastasis abilities of cancer cells. FGFR-IN-28 exhibits anti-tumor activity in in vitro experiments on colon cancer cells, and inhibits tumor growth in colon cancer xenograft models. FGFR-IN-28 can be used in colon cancer-related research. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
FGFR-IN-29
0 ImagesArt. -Nr.: HY-189241FGFR-IN-29 is an orally active pan-FGFR inhibitor that suppresses the kinase activities of FGFR1, FGFR2, FGFR3, and FGFR4. FGFR-IN-29 blocks the intracellular phosphorylation process of FGFR and arrests downstream tumor cell proliferation signaling. FGFR-IN-29 inhibits tumor growth in solid tumor xenograft mouse models. FGFR-IN-29 is applicable for cancer-related research. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
FGFR2/4 ligand-2
0 ImagesArt. -Nr.: HY-191675FGFR2/4 ligand-2 is a Ligands for Target Protein for PROTAC targeting FGFR2 and FGFR4, and can be used to synthesize PROTAC FGFR2/4 degrader 2 (HY-191674). -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
-
FGFR1-IN-19
0 ImagesArt. -Nr.: HY-191441CAS. Nr.: 2991245-67-9FGFR1-IN-19 is a selective, orally active, irreversible, covalent FGFR1 inhibitor with an IC50 of 7.6 nM. FGFR1-IN-19 reduces the phosphorylation levels of PLCγ, AKT, and ERK. FGFR1-IN-19 induces G0/G1 phase arrest and Caspase-dependent Apoptosis. FGFR1-IN-19 can be used for research on FGFR1-amplified lung cancer. -
loading...Please select quantityAngebot einholen
August 31
-
Please select quantity
August 31
Angebot einholen
loading... -
- 1
- 2